Effects and preliminary molecular mechanisms of papain on the inhibition of monocyte secretory and adherent ability induced by monocyte-platelet aggregates

Abstract

Abstract:

AIM: To observe the inhibitory effects of papain on monocyte secretory and adherent ability induced by monocyte-platelet aggregates (MPA), and to explore the preliminary molecular mechanisms. METHODS: Monocyte and platelet rich plasma were separated form human peripheral blood. Platelet were activated by thrombin and arachidonic acid, then mixed with monocyte in 20 U/L of papain,respectively, and levels of MPA and TNF-α were determined.The study was further divide into three groups: 0 (control), 20, 80 U/L of papain group activated by 10 U/L thrombin, MCP-1, tissue factor (TF), CD11b and CCR2 expression, and adherent monocyte percent were measured by ELISA, flow cytometry, and microscopic examination, respectively.Western blot analysis was used to detect the phosphorylated Akt and COX-2 expression.RESULTS:In incubated with monocyte and platelet, 20 U/L of papain significantly decreased MPA formation and TNF-α levels induced by thrombin and arachidonic acid (P<0.01) . In 20 U/L of papain group, MCP-1, TF, CD11b and CCR2 expression levels, and adherent monocyte percent were significantly decreased compared with control group (P<0.01).The inhibitory percent of the abovementioned five markers were increased in 80 U/L group than that in 20 U/L group (P<0.01). Papain significantly inhibited Akt phosphorylation and COX-2 expression, there were lower photodensity ratios in 80 U/L group than that in 20 U/L group (P<0.01). CONCLUSION: Papain may inhibit monocyte secretory and adherent ability induced by monocyte-platelet aggregates through the inhibition of Akt phosphorylation and COX-2 expression, and can be used to prevent atherosclerosis.

Key words: papain, monocyte-platelet aggregates, monocyte activation, Akt phosphorylation, COX-2

CLC Number:

R965.2

FEI Xianming, WANG Huan, YUAN Wufeng, JIANG Lei, CHENG Maoliang. Effects and preliminary molecular mechanisms of papain on the inhibition of monocyte secretory and adherent ability induced by monocyte-platelet aggregates[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 1-8.

References

［1］Gkaliagkousi E, Corrigall V, Becker S, et al. Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension［J］. Eur Heart J, 2009, 30(24): 3048-3054.
［2］李环，焦亚斌. 丹参饮精品中药与普通中药对动脉粥样硬化模型大鼠药理作用的比较［J］. 长春中医药大学, 2014, 30(12): 978-979.
［3］Vigetti D, Genasetti A, Karousou E, et al. Proinflammatory cytokines induce hyaluronan synthesis and monocyte adhesion in human endothelial cells through hyaluronan synthase 2 (HAS2) and the nuclear factor-κB (NF-κB) pathway［J］. J Biol Chem, 2010, 285(32): 24639-24645.
［4］费鲜明, 周永列, 祁金文, 等. 木瓜蛋白酶体外对血小板聚集的抑制作用［J］. 中国临床药理学与治疗学, 2009, 14(8): 906- 911.
［5］蒋雷，费鲜明，苗成霖，等. 木瓜蛋白酶对MPA形成及其诱导的单核细胞活化的影响［J］. 中国临床药理学与治疗学，2015, 20(3)：289-292.
［6］刘文彬，褚夫江，吴玉萍, 等. 罗仙子提取物对单核细胞与血管内皮细胞黏附的影响［J］.中国临床药理学与治疗学，2014，19（7）：752-755.
［7］王佐，吕运成，危当恒，等. 基质细胞衍生因子1α对大鼠血管平滑肌细胞与单核细胞粘附的影响［J］. 中国动脉硬化杂志，2006，9：759-762.
［8］Hansson GK, Hermansson A. The immune system in atherosclerosis［J］. Nat Immunol, 2011, 12(3): 204-212.
［9］Van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases［J］. J Leu Biol, 2009, 85(2): 195-204.
［10］Esch JSA, Jurk K, Knoefel WT, et al. Platelet activation and increased tissue factor expression on monocytes in reperfusion injury following orthotopic liver transplantation［J］. Platelets, 2010, 21(5): 348-359.
［11］Passacquale G, Vamadevan P, Pereira L, et al. Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes［J］. PLoS One,2011, 6(10): e25595.
［12］苏林丘, 陈德伟. 单核细胞趋化蛋白1及其受体 CCR2 与冠心病关系的研究进展［J］. 医学综述，2011，17（16）：2411-2414.
［13］Fadini GP, Simoni F, Cappellari R, et al. Pro-inflammatory monocyte-macrophage polarization imbalance in human hypercholesterolemia and atherosclerosis［J］. Atherosclerosis, 2014, 237 (2): 805-808.
［14］Duo CC, Gong FY, He XY, et al. Soluble calreticulin induces tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 production by macrophages through Mitogen-Activated Protein Kinase (MAPK) and NF-κB signaling pathways［J］. Int J Mol Sci, 2014, 15(2): 2916-2928.
［15］Schulz C, Von Brühl ML, Barocke V, et al. EMMPRIN (CD147/basigin) mediates platelet-monocyte interactions in vivo and augments monocyte recruitment to the vascular wall［J］. J Throm Haem, 2011, 9(5): 1007-1019.
［16］Meng F, Liu L, Chin PC, et al. Akt is a downstream target of NF-κB［J］. J Biol Chem, 2002, 277(33): 29674-29680.
［17］Kim KS, Lee DS, Bae GS, et al. The inhibition of JNK MAPK and NF-κB signaling by tenuifoliside A isolated from Polygala tenuifolia in lipopolysaccharide-induced macrophages is associated with its anti-inflammatory effect［J］. Euro J Pharmacol, 2013, 721(1): 267-276.
［18］Dixon DA, Tolley ND, Bemis-Standoli K, et al. Expression of COX-2 in platelet- monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling［J］. J Clin Invest, 2006, 116(10): 2727.
［19］Pettus BJ, Bielawski J, Porcelli AM, et al. The sphingosine kinase 1/sphingosine- 1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-α［J］. FASEB J, 2003, 17(11): 1411-1421.

[1]	WANG Jinhuo, GAO Xinyue, GUO Jianrong. Effect of COX-2 inhibitors on postoperative delirium in elderly patients undergoing orthopedic surgery and its possible mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 863-869.
[2]	LI Minjiang, CHEN Dong, CHEN Wenbin. Effects of beta-adrenergic receptor blockers and COX-2 inhibitors on liver metastasis of colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 893-899.
[3]	WANG Jue,QIAO Qing, CHENG Maoliang, LI Wanchun, WANG Yipin, YING Wei. Effects of Ginkgo biloba tablet on MPA, CD11b and MCP-1 levels in patients with unstable angina pectoris [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1421-1425.
[4]	JIANG Lei, FEI Xian-ming, MIAO Cheng-lin, YUAN Wu-feng, QIU Lian-nv. Effects of papain on monocyte-platelet aggregates formation and monocyte activation induced by monocyte-platelet aggregates [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 289-292.
[5]	LUO Hui-ying, YANG Lin, WANG Xiao-peng, SU He, LIU Ying, MA Yun-tao, WU Zi-yan. Effects of siRNA silencing COX-2 gene on VEGF-C expression and cell migration in SGC-7901 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 961-966.
[6]	ZUO Lei, LIU Dan-yan, LI Qi-ying. Curcumin mitigates the changes of cognitive function by sevoflurane anesthesia in aged rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(6): 638-643.
[7]	FENG Zheng-quan, LIN Xiao-yang, HAO Wan-rong. Effect of tetrastigma hemsleyanum diels et gilg flavone on the immunosuppressive associated cytokines in Lewis lung cancer mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 275-279.
[8]	SONG Shu-hui, HU Xin, XIONG Yu-qing, CAI Li-ping. Effects of Naringin on expression of COX-2 mRNA and protein in Human ovarian cancer cell line SKOV3 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 271-275.
[9]	XU Wei-hong, LV Yuan-dong, TAO Ping-hua, WU Guo-you, YU Wei, HU Xi-lia. In vitro inhibitory effect of papain on blood coagulation function and the related mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 166-170.
[10]	WU Ke, XIE Ling-Yao, YANG Jun-qin. Effects of COX-2 overexpression on hippocampal neuronal damage induced by aluminum in rat [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 967-971.
[11]	WU Ke, HE Bai-cheng, ZHOU Qi-xin. Chemoprevention effect of Rosiglitazone on the experimental colon cancer in rat [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(10): 1124-1129.
[12]	FEI Xian-ming, ZHOU Yong-lie, QI Jin-wen, WU Jian-guo, QIU Lian-nv, WANG Zhen-ni. In vitro inhibitory effects of papain on platelet aggregation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(8): 906-911.
[13]	LU Li-na, YANG Ting , ZHUANG Ze-hao. Role of cyclooxyenase and its inhibitors in prevention and treatment of can- cer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(1): 22-26.
[14]	LIU Wei, Loo CC, QIN Xiao-tao, HUANG Yu-guang. Effect of etoricoxib on postoperative patient-controlled analgesia in major gynecological operation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(9): 984-987.
[15]	LI Qin, WANG Rui, CHEN Kun. Analysis of withdrawal of rofecoxib-cyclooxygenase-2 specific inhibitor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(3): 259-264.